These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23388592)

  • 1. [The vertebral artery syndrome and patient management tactics].
    Panteleeva EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(12):46-50. PubMed ID: 23388592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of injectable sermion in otologic diseases].
    Gaillard J; Dubreuil C
    J Fr Otorhinolaryngol Audiophonol Chir Maxillofac; 1979 Sep; 28(7):477-80. PubMed ID: 41025
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic potential and possibilities of using of sermion (nicergoline) in neurological practice].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2010; 110(12):119-22. PubMed ID: 21434467
    [No Abstract]   [Full Text] [Related]  

  • 4. [Short-term and long-term results of treatment of chronic arteriopathies of the lower limbs with nicergoline. Importance of intensive medical therapy].
    Quiroli A
    Minerva Cardioangiol; 1980 Dec; 28(12):793-804. PubMed ID: 6111767
    [No Abstract]   [Full Text] [Related]  

  • 5. [Alpha-blockers and treatment of coronary artery vasospasm].
    Weber S; Chapsal J; Pipeau C; Degeorges M
    Arch Mal Coeur Vaiss; 1983 Feb; 76 Spec No():131-6. PubMed ID: 6134505
    [No Abstract]   [Full Text] [Related]  

  • 6. [Influence of nicergoline on the cerebral blood flow and alpha-sympatholytical properties (author's transl)].
    Lievre M; Ollagnier M; Faucon G
    Arzneimittelforschung; 1979; 29(8a):1227-31. PubMed ID: 44198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic possibilities of nicergoline in neurogenic bladder dysfunction].
    Gallego Gómez J; Jiménez Cruz JF; Martínez Agulló E; Mompó Sanchís JA; Llopis Mínguez B; Boronat Tormo F
    Arch Esp Urol; 1985; 38(2):175-90. PubMed ID: 2862846
    [No Abstract]   [Full Text] [Related]  

  • 8. [Sermion in the treatment of patients with neurological diseases].
    Kovalenko PA; Kolomoets IuV; Seropegin AD
    Voen Med Zh; 2001 Aug; 322(8):49-50. PubMed ID: 11569346
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current aspects of rehabilitation of stroke patients].
    Koval'chuk VV; Bogatyreva MD; Minullin TI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(6):101-5. PubMed ID: 25075422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of sermion on the main hemodynamic indices in patients with the initial manifestations of cerebral atherosclerosis].
    Tokar' AV; Akhaladze NG; Ena LM; Rudaia ES; Severova NL
    Vrach Delo; 1990 Feb; (2):27-30. PubMed ID: 2339544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of Sermion in the treatment of tinnitus noise in patients with chronic cerebrovascular pathology].
    Ekusheva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10):60-66. PubMed ID: 34874656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicergoline in the treatment of dizziness in elderly patients. A review.
    Felisati G; Pignataro O; Di Girolamo A; Bruno E; Alessandrini M; Guidetti G; Monzani D; Beldi AM; Mira E; Benazzo M; Pallestrini E; Caligo G; Casani A; Battaglia A
    Arch Gerontol Geriatr Suppl; 2004; (9):163-70. PubMed ID: 15207410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of neurotrophic keratopathy with nicergoline.
    Lee YC; Kim SY
    Cornea; 2015 Mar; 34(3):303-7. PubMed ID: 25625360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nicergoline: parallel evolution of clinical trial methodology and drug development in dementias.
    Crook TH
    Dement Geriatr Cogn Disord; 1997; 8 Suppl 1():22-6. PubMed ID: 9205835
    [No Abstract]   [Full Text] [Related]  

  • 15. [Use of nicergoline (Sermion) in the treatment of migraine].
    Prusiński A; Durko A; Selmaj K
    Wiad Lek; 1984 Mar; 37(6):420-2. PubMed ID: 6385484
    [No Abstract]   [Full Text] [Related]  

  • 16. [Sermion treatment of middle-aged and elderly patients with initial atherosclerotic encephalopathy].
    Man'kovskiĭ NB; Mints AIa; Bachinskaia NIu; Kochubeĭ NV
    Vrach Delo; 1989 Apr; (4):60-3. PubMed ID: 2756691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of sermion on brain function in diabetics].
    Efimov AS; Man'kovskiĭ BN
    Vrach Delo; 1991 Nov; (11):73-6. PubMed ID: 1801441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interaction between anti-aggregating and anticoagulant agents. A double blind study on the concomitant administration of nicergoline and acenocoumarols].
    Pogliani E; Recalcati P; Tantalo V; Bregnani P
    Arzneimittelforschung; 1979; 29(8a):1266-9. PubMed ID: 395954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of demonstrated cerebral ischemia with nicergoline (Sermion)].
    Karyofilis A
    Ther Ggw; 1980 Dec; 119(12):1478-85. PubMed ID: 7466692
    [No Abstract]   [Full Text] [Related]  

  • 20. [Influence of arterial hypertension on the clinical course of Parkinson's disease (PD) among middle-aged patients].
    Karasevich NV; Karaban' NV
    Lik Sprava; 2007; (5-6):60-4. PubMed ID: 18416166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.